The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Official Title: Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer
Study ID: NCT00553358
Brief Summary: This is a randomised, open label multicenter Phase III study comparing the efficacy of neoadjuvant lapatinib plus paclitaxel, versus trastuzumab plus paclitaxel, versus concomitant lapatinib and trastuzumab plus paclitaxel given as neoadjuvant treatment in HER2/ErbB2 over-expressing and/or amplified primary breast cancer. Patients will be randomised to receive either: lapatinib 1500 mg daily, trastuzumab 4 mg/kg intravenous (IV) load followed by 2 mg/kg IV weekly, or lapatinib 1000 mg daily with trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV weekly for a total of 6 weeks. After this biological window, patients on monotherapy arms will continue on the same targeted therapy plus weekly paclitaxel 80 mg/m\^2 for a further 12 weeks, up to definitive surgery. In the combination arm, patients will receive lapatinib 750 mg daily in combination with trastuzumab 2 mg/kg IV plus weekly paclitaxel 80mg/m\^2 IV for a further 12 weeks, up to definitive surgery. After surgery, patients will receive three courses of adjuvant chemotherapy with 5-Fluorouracil Epirubicin Cyclophosphamide (FEC) followed by the same targeted therapy as in the biological window of the neoadjuvant setting for a further 34 weeks (in the combination arm, lapatinib dose will be 1000 mg daily in combination with trastuzumab). The planned total duration of the anti-HER2 therapy one year. Primary objective is to evaluate and compare the rate of pathological complete response (pCR) at the time of surgery in patients with HER2/ErbB2 overexpressing or amplified operable breast cancer randomised to lapatinib followed by lapatinib plus paclitaxel versus trastuzumab followed by trastuzumab plus paclitaxel versus lapatinib in combination with trastuzumab followed by lapatinib, trastuzumab plus paclitaxel.
Detailed Description: This was a parallel group, three-arm, randomized, multicenter, open-label phase III study. The study compared the efficacy and tolerability of neoadjuvant lapatinib and paclitaxel, versus trastuzumab and paclitaxel, versus the combination of lapatinib with trastuzumab and paclitaxel given as neoadjuvant treatment in HER2/ErbB2 over-expressing and/or amplified primary breast cancer. Subjects were randomized to receive lapatinib, trastuzumab or lapatinib plus trastuzumab for a total of 6 weeks. After this biological window, subjects continued on the same targeted therapy plus weekly paclitaxel for a further 12 weeks, until definitive surgery (total neoadjuvant therapy duration of 18 weeks). Paclitaxel could be initiated at Week 4 if there is evidence of progressive disease (PD) at that time. Within 6 weeks after surgery, subjects received 3 cycles of adjuvant 5-flourouracil, epirubicin and cyclophosphamide (FEC) followed by the same targeted therapy as in the biological window of the neoadjuvant phase for a further 34 weeks (to complete 52 weeks of anti-HER2 therapy). After completing 52 weeks of (neo-)/adjuvant anti-HER2 therapy, subjects were scheduled to attend post-treatment follow-up every 3 months during the first year (months 12, 15, 18, 21, and 24), every 6months in Years 3 to 5 inclusive, and annually thereafter up to Year 10. Each subject was to be followed for 10 Years. All subjects were to be followed for EFS and OS up to 10 years from last subject randomized.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Novartis Investigative Site, Berazategui, Buenos Aires, Argentina
Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site, Rosario, Santa Fe, Argentina
Novartis Investigative Site, Quilmes, , Argentina
Novartis Investigative Site, Santa Fe, , Argentina
Novartis Investigative Site, Tucuman, , Argentina
Novartis Investigative Site, Brussels, , Belgium
Novartis Investigative Site, Brussel, , Belgium
Novartis Investigative Site, Bruxelles, , Belgium
Novartis Investigative Site, Gent, , Belgium
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Namur, , Belgium
Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil
Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil
Novartis Investigative Site, Santo Andre, São Paulo, Brazil
Novartis Investigative Site, Sao Paulo, São Paulo, Brazil
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Brno, , Czechia
Novartis Investigative Site, Novy Jicin, , Czechia
Novartis Investigative Site, Praha 10, , Czechia
Novartis Investigative Site, Bayonne, , France
Novartis Investigative Site, Bordeaux, , France
Novartis Investigative Site, Le Mans, , France
Novartis Investigative Site, Levallois-Perret, , France
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Reims, , France
Novartis Investigative Site, Strasbourg, , France
Novartis Investigative Site, Strasbourg, , France
Novartis Investigative Site, Toulouse, , France
Novartis Investigative Site, Villejuif Cedex, , France
Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany
Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany
Novartis Investigative Site, Fuerth, Bayern, Germany
Novartis Investigative Site, Nuernberg, Bayern, Germany
Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany
Novartis Investigative Site, Frankfurt am Main, Hessen, Germany
Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany
Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany
Novartis Investigative Site, Celle, Niedersachsen, Germany
Novartis Investigative Site, Hannover, Niedersachsen, Germany
Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany
Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany
Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany
Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany
Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany
Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Hong Kong, , Hong Kong
Novartis Investigative Site, Kowloon, , Hong Kong
Novartis Investigative Site, Wanchai, , Hong Kong
Novartis Investigative Site, Budapest, , Hungary
Novartis Investigative Site, Bangalore, , India
Novartis Investigative Site, Hyderabad, , India
Novartis Investigative Site, Mumbai, , India
Novartis Investigative Site, Nagpur, , India
Novartis Investigative Site, New Delhi, , India
Novartis Investigative Site, New Delhi, , India
Novartis Investigative Site, Pune, , India
Novartis Investigative Site, Roma, Lazio, Italy
Novartis Investigative Site, Genova, Liguria, Italy
Novartis Investigative Site, Lecco, Lombardia, Italy
Novartis Investigative Site, Milano, Lombardia, Italy
Novartis Investigative Site, Milano, Lombardia, Italy
Novartis Investigative Site, Monza, Lombardia, Italy
Novartis Investigative Site, Sondrio, Lombardia, Italy
Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Songpa-gu, Seoul, , Korea, Republic of
Novartis Investigative Site, Vilnius, , Lithuania
Novartis Investigative Site, Oslo, , Norway
Novartis Investigative Site, Oslo, , Norway
Novartis Investigative Site, Karachi, , Pakistan
Novartis Investigative Site, Lima, , Peru
Novartis Investigative Site, Lima, , Peru
Novartis Investigative Site, Bucharest, , Romania
Novartis Investigative Site, Bucharest, , Romania
Novartis Investigative Site, Bucuresti, , Romania
Novartis Investigative Site, Cluj-Napoca, , Romania
Novartis Investigative Site, Moscow, , Russian Federation
Novartis Investigative Site, Ryazan, , Russian Federation
Novartis Investigative Site, St. Petersburg, , Russian Federation
Novartis Investigative Site, St. Petersburg, , Russian Federation
Novartis Investigative Site, Pretoria, Gauteng, South Africa
Novartis Investigative Site, Athlone Park, Amanzimtoti, , South Africa
Novartis Investigative Site, Capital Park, , South Africa
Novartis Investigative Site, Parktown, , South Africa
Novartis Investigative Site, Barcelona, , Spain
Novartis Investigative Site, Girona, , Spain
Novartis Investigative Site, Lerida, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Mataro, , Spain
Novartis Investigative Site, Santiago de Compostela, , Spain
Novartis Investigative Site, Sevilla, , Spain
Novartis Investigative Site, Toledo, , Spain
Novartis Investigative Site, Torrevieja (Alicante), , Spain
Novartis Investigative Site, Valencia, , Spain
Novartis Investigative Site, Goteborg, , Sweden
Novartis Investigative Site, Changhua, , Taiwan
Novartis Investigative Site, Tainan, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Chernivtsi, , Ukraine
Novartis Investigative Site, Dnipropetrovsk, , Ukraine
Novartis Investigative Site, Kharkiv, , Ukraine
Novartis Investigative Site, Kiev, , Ukraine
Novartis Investigative Site, Krivoy Rog, , Ukraine
Novartis Investigative Site, Kyiv, , Ukraine
Novartis Investigative Site, Lviv, , Ukraine
Novartis Investigative Site, Odessa, , Ukraine
Novartis Investigative Site, Simferopol, , Ukraine
Novartis Investigative Site, Epping, Essex, United Kingdom
Novartis Investigative Site, Bournemouth, , United Kingdom
Novartis Investigative Site, London, , United Kingdom
Novartis Investigative Site, London, , United Kingdom
Novartis Investigative Site, Nottingham, , United Kingdom
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR